← Evidence map

ArticleHaematologica2013

Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements.

Andrew Chase et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

18 papers cite it

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 22875628